Trius Therapeutics (TSRX)
Trius Therapeutics PE Ratio
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TSRX PE Ratio Range, Past 5 Years
| Minimum | 1.117 | Sep 2011 |
| Maximum | 2.489 | Mar 2011 |
| Average | 1.778 |
About Price to Earnings Ratio
The price to earnings ratio (PE Ratio) is the measure of the share price relative to the annual net income earned by the firm per share. PE ratio shows current investor demand for a company share. A high PE ratio generally indicates increased demand because investors anticipate earnings growth in the future. The PE ratio has units of years, which can be interpreted as the number of years of earnings to pay back purchase price.
PE ratio is often referred to as the "multiple" because it demonstrates how much an investor is willing to pay for one dollar of earnings. PE Ratios are sometimes calculated using estimations of next year's earnings per share in the denominator. When this happens, it is usually noted.
Learn More
You may also be interested in these TSRX related companies
TSRX News
$TSRX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3KJ0
about 50 days ago by MarketBrief
about 50 days ago by MarketBrief
Piper Jaffray Sees Increased Chance of Trius (TSRX) Partnering in Europe Following Tedizolid Data
Apr 09, 2:49PM Street Insider
Apr 09, 2:49PM Street Insider
Trius Therapeutics (TSRX) Reports Encouraging Data for TR701-112 in Cellulitis Patients
Apr 02, 7:10AM Street Insider
Apr 02, 7:10AM Street Insider
Trius' Antibiotic Tedizolid Demonstrates High Efficacy in Patients With Cellulitis
Apr 02, 7:00AM GlobeNewswire
Apr 02, 7:00AM GlobeNewswire
$TSRX http://stks.co/36wB undervalued (IMHO) bioname, double bottomed just below 5$, can go higher now - $TSRX
about 65 days ago by LTbioinvestor
about 65 days ago by LTbioinvestor
Trius Therapeutics (TSRX) Posts Narrower than Expected Q4 Loss of 44c/Share
Mar 13, 8:12AM Street Insider
Mar 13, 8:12AM Street Insider
Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial Results
Mar 13, 8:00AM GlobeNewswire
Mar 13, 8:00AM GlobeNewswire
$TSRX New 52 Week Low - Crossed daily lows support. Next support 4.60 from 2/17/2011.
about 85 days ago by TradeIdeasQuant
about 85 days ago by TradeIdeasQuant
$TSRX New 52 Week Low - Crossed daily lows support. Next support 4.90 from 2/18/2011.
about 87 days ago by TradeIdeasQuant
about 87 days ago by TradeIdeasQuant
$TSRX http://stks.co/2ds5 Biotech name. Bullish engulfing. Falling wedge.
about 91 days ago by VexTrades
about 91 days ago by VexTrades
$TSRX New 52 Week Low - Crossed daily lows support. Next support 4.90 from 2/18/2011.
about 92 days ago by TradeIdeasQuant
about 92 days ago by TradeIdeasQuant
I think $TSRX is worth accumulating in here. I also continue to add $CJES
about 122 days ago by britepathos
about 122 days ago by britepathos
Trius Therapeutics (TSRX) Underwriters Exercise Full Overallotment in Recent Offering
Jan 30, 7:05AM Street Insider
Jan 30, 7:05AM Street Insider
Baird Said Trius Therapeutics (TSRX) Equity Offering News Provides Attractive Entry Point
Jan 26, 9:58AM Street Insider
Jan 26, 9:58AM Street Insider
Trius Therapeutics (TSRX) Prices 8.6 Million Share Offering at $5.25/Share
Jan 26, 9:06AM Street Insider
Jan 26, 9:06AM Street Insider
$TSRX Announces Proposed Public Offering of Common Stock; Size Not Given
about 128 days ago by Benzinga
about 128 days ago by Benzinga
Buying Opportunity In Trius Therapeutics http://stks.co/22tw // $TSRX
about 130 days ago by JNapodano
about 130 days ago by JNapodano
Updated report on $TSRX: http://stks.co/1QHF // R&D Day Highlights Why Tedizolid Could Be "Best-In-Class" for #MRSA.
about 177 days ago by JNapodano
about 177 days ago by JNapodano
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TSRX | 5.13 | +0.12 | +2.40% | 193.19M |
| TSRI | 4.24 | +0.00 | +0.00% | 8.438M |
| TSRA | 13.59 | -0.10 | -0.73% | 709.83M |
| TSPT | 7.08 | -0.02 | -0.28% | 98.69M |
| TSON | 2.93 | -0.05 | -1.68% | 81.20M |
| TSO | 22.12 | -1.09 | -4.70% | 3.265B |
| TSM | 13.73 | -0.20 | -1.44% | 72.20B |
| TNB | 71.99 | +0.00 | +0.00% | 3.758B |
| TNAV | 6.01 | +0.20 | +3.44% | 241.81M |
| TNA | 47.26 | -0.31 | -0.65% |
